Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30

$0.83−0.01 (-0.93%)

Close on Nov 11, 2026Market cap $149.51MP/E –Yield –

Compass Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

Compass Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Parsed from the XBRL in Compass Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 4-for-3 split on Aug 13, 2020
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CMPX.

Advertisement
300 × 250

See a number that looks wrong?